A lawsuit was filed by an investor in shares of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) in effort to stop the proposed takeover and NASDAQ:ONXX stockholders should contact the Shareholders Foundation.

San Diego, CA -- (SBWire) -- 09/04/2013 --An investor who currently holds shares of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) filed a lawsuit in effort to halt the proposed takeover of Onyx Pharmaceuticals, Inc. by Amgen for $125 per NASDAQ:ONXX share.

Investors who purchased shares of the Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and currently hold any of those NASDAQ:ONXX shares have certain options and should contact the Shareholders Foundation at mail(at)shareholdersfoundation.com or call +1(858) 779 - 1554.

The plaintiff alleges that the defendants breached their fiduciary duties by ageing to sell Onyx Pharmaceuticals too cheaply to Amgen.

On Jun. 30, 2013, Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) confirmed that it has received and rejected an unsolicited proposal from Amgen Inc. to acquire all of Onyx Pharmaceuticals’ outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions. Then on Aug. 25, 2013, Amgen (NASDAQ:AMGN) and Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) announced that their Boards of Directors have unanimously approved a transaction under which Amgen will acquire all of the outstanding shares of Onyx Pharmaceuticals, Inc. for $125 per share in cash.

However, the plaintiff claims that the offer is too low and undervalues the company. Indeed, after the June 30, 2013 announcement NASDAQ:ONXX shares jumped in the open market to $136.03 per share on July 5, 2013. Moreover, the plaintiff alleges that the offer price is significantly below the $160-target prices for Onyx Pharmaceuticals’ stock set by analysts.

Furthermore, the plaintiff says that the process is unfair as well. The plaintiff claims that the defendants agreed to preclusive deal protection devices, such as a $303 million termination fee.

On September 3, 2013, NASDAQ:ONXX shares closed at $123.74 per share.

Those who are current investors in Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and purchased their NASDAQ:ONXX shares prior to the announcement, have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Joelle Day
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com